Select therapeutic use:
Indications for RETROVIR IV:
HIV infection, in combination with other antiretrovirals. Prevention of maternal-fetal HIV transmission.
Give by IV infusion over 1hr; use only until oral therapy can be given. 1mg/kg every 4hrs. Renal impairment (CrCL <15mL/min) or on dialysis: 1mg/kg every 6–8hrs. Prevention of maternal-fetal HIV or vertical transmission, severe anemia and/or neutropenia: see full labeling.
Vertical transmission: see full labeling.
Risk of hematological toxicity. Myopathy. Lactic acidosis and severe hepatomegaly with steatosis.
Suspend if lactic acidosis or hepatotoxicity (eg, hepatomegaly and steatosis) occurs. Monitor for hematologic toxicity; reduce dose or suspend if significant anemia and/or granulocytopenia occurs; transfuse if necessary. Risk of myopathy with prolonged use. Renal or hepatic dysfunction: consider reducing dose. Bone marrow suppression. Risk of liver disease. Women, obesity, prolonged nucleoside exposure, or advanced HIV disease: increased risk of toxicity. Monitor for lipoatrophy; if suspected, switch to alternative therapy. Latex allergy (IV). Elderly. Pregnancy. Nursing mothers: not recommended.
Nucleoside analogue (reverse transcriptase inhibitor).
Avoid stavudine, doxorubicin, ribavirin, other nucleoside analogues. Caution with other cytotoxic or myelosuppressive drugs (eg, ganciclovir, interferon-alpha, ribavirin). Potentiated by fluconazole, atovaquone, lamivudine, probenecid, valproic acid, methadone. Monitor phenytoin. May be antagonized by clarithromycin, rifampin, ritonavir, nelfinavir. Monitor for treatment-associated toxicities with interferon-alpha with or without ribavirin.
Headache, malaise, nausea, vomiting, anorexia, insomnia, pain, neuropathy, myositis, thrombocytopenia, anemia, neutropenia, myopathy, lactic acidosis, steatosis, hepatomegaly, immune reconstitution syndrome, pancreatitis, others. Children: also fever, cough.
Tabs—contact supplier; Caps—100; Syrup—240mL; IV (20mL/vial)—10